The published mean half-life of retatrutide is about 6 days. A 2026 review of the phase 1 and phase 2 pharmacokinetic reports states that exposure rose in proportion to the amount given and that a mean half-life of roughly 6 days fits a once-weekly design. That figure describes how fast the molecule clears from the body in the clinical studies. It is not a shelf life, and it says nothing about how long a lyophilized vial or a reconstituted solution stays intact. Those are separate clocks, covered below.
Retatrutide half-life at a glance
| Item | Detail | Source |
|---|---|---|
| Reported mean half-life | About 6 days | Tetelbaun 2026 |
| Exposure pattern | Dose proportional in the phase 1 and 2 reports | Tetelbaun 2026 |
| Molecule | Retatrutide (LY3437943), a lipidated 39-residue peptide acting at the GIP, GLP-1 and glucagon receptors | Mateescu 2026; Coskun 2022 |
| Design intent | Pharmacokinetic profile described as supporting once-weekly use in the first single-ascending-dose study | Coskun 2022 |
| What half-life is not | Vial shelf life or stability of a reconstituted solution | See the three clocks below |
| V8 lab reports | Retatrutide 10 mg and 20 mg, Accumark Labs HPLC purity and identity | COA page |
Last reviewed November 21, 2026 by the V8 Peptides Research Team. Each reference links to its PubMed record. For laboratory research use only.
What "half-life" means
A half-life is the time it takes for the concentration of a substance to fall to half of its starting value. Most peptide clearance is modelled as first-order: the same fraction disappears in each equal block of time, however much is present. That is why one number is enough to describe the whole decay curve, and why the figure is quoted as a mean across the people or animals measured. A published half-life is a property of a molecule in a given species and study, not a constant of the compound.
What the published sources report for retatrutide
Three papers carry most of what is public. The discovery and first-in-human paper from Eli Lilly (Coskun et al., 2022) describes LY3437943 as a triple agonist at the glucagon, GIP and GLP-1 receptors and reports that, in a phase 1 single-ascending-dose study, its pharmacokinetic profile supported a once-weekly design. A 2026 review in Cardiology in Review (Tetelbaun et al.) summarises the phase 1 and 2 reports and gives the number most people are searching for: pharmacokinetics were dose proportional, with a mean half-life of approximately 6 days. A second 2026 review (Mateescu et al.) describes retatrutide as an investigational, once-weekly, lipidated 39-residue peptide and lists scalable synthesis, impurity and potency control and formulation stability among its pharmaceutical priorities.
The sources agree with each other, but they are narrative summaries of clinical programmes. They give the mean, not the spread between individuals, and they do not tell a bench scientist how the molecule behaves in a different species, a different matrix or a different buffer.
Why a lipidated peptide lasts longer than a plain one
Fatty-acid modification is a design feature used to slow the clearance of incretin peptides. The semaglutide discovery paper (Lau et al., 2015) is the clearest public example: the fatty acid and the chemistry linking it to the peptide were chosen to raise albumin affinity and to protect the chain from enzymatic breakdown, and the plasma half-life measured in mini-pigs after intravenous delivery was 46.1 hours, with a mean residence time of 63.6 hours after subcutaneous delivery. A later review (Knudsen and Lau, 2019) describes reversible albumin binding as the mechanism used to extend the action of liraglutide and semaglutide. Retatrutide is described as lipidated (Mateescu 2026), which is consistent with the same general strategy.
Notice the species in that semaglutide example. A mini-pig value is not a human value and neither is a rat value. When a lab reads a half-life in a paper, the first question is which species and route produced it.
The arithmetic of a 6-day half-life
If a first-order model with a 6-day half-life is assumed, the fraction remaining after time t is 0.5 raised to the power of t divided by 6. The table shows the result at whole half-lives. It is an illustration of the formula, not a prediction for any experiment.
| Elapsed days | Half-lives | Fraction remaining |
|---|---|---|
| 0 | 0 | 100% |
| 6 | 1 | 50% |
| 12 | 2 | 25% |
| 18 | 3 | 12.5% |
| 24 | 4 | 6.25% |
| 30 | 5 | 3.125% |
The same formula works in reverse for study planning: to find how many half-lives separate two sampling times, divide the gap in days by 6. The reconstitution calculator handles the separate question of concentration in a vial.
Three clocks that get confused
| Clock | What it measures | Where to read about it |
|---|---|---|
| Biological half-life | How fast the molecule clears in a living system | Pharmacokinetic papers (this page) |
| Lyophilized stability | How long sealed dry powder stays intact in the vial | Retatrutide storage and stability |
| Solution stability | How long a reconstituted solution stays intact once made up | How long reconstituted peptides last |
A 6-day biological half-life does not mean a prepared solution lasts 6 days, and it does not shorten or lengthen the life of a sealed vial. The three are governed by different chemistry: clearance depends on the biology of the living system, while vial and solution stability depend on moisture, temperature, pH and the handling of the material. Our semaglutide half-life and stock stability article draws the same line for a sister molecule.
Using a published half-life in laboratory work
Cell-based receptor assays have no clearance, so a half-life figure does not enter them at all; what matters there is the stability of the working solution over the length of the assay. In animal studies, the half-life of the study species controls how often samples need to be taken, and that has to come from the study's own pilot data or from a paper in the same species. Carrying a clinical mean across to a rodent or a mini-pig is the commonest way to mis-time a sampling schedule. Reading the units matters too: papers report terminal half-life, mean residence time and apparent half-life, and they are not interchangeable.
What a V8 report shows for retatrutide
V8 supplies retatrutide for laboratory research only, in 10 mg and 20 mg vials. The Accumark Labs report for the 10 mg lot (published 10/18/2026) lists identity as conforming, a measured quantity of 9.944 mg against the 10.0 mg label and HPLC purity of 99.96% against a specification above 98.0%. The 20 mg report (published 09/10/2026) lists 20.25 mg measured against 20.0 mg and purity of 99.972%. Both reports include an endotoxin (LAL) line with a limit of 5.0 EU/mL or less. A report like this establishes what is in the tested sample. It does not measure half-life or stability, which is why those questions are answered from the literature and from the handling articles above.
For background on the compound itself, see what "reta" means and the retatrutide research overview; for sourcing questions, where to buy retatrutide for research.
Frequently asked questions
What is the half-life of retatrutide?
A 2026 review of the phase 1 and phase 2 pharmacokinetic reports gives a mean half-life of approximately 6 days, with dose-proportional exposure. It is a clinical average, not a constant for every system.
Is retatrutide half-life the same as how long the vial lasts?
No. Half-life describes clearance in a living system. Vial stability and solution stability depend on moisture, temperature, pH and handling, and are covered in the storage and reconstituted-peptide articles.
Why is a lipidated peptide cleared more slowly?
Fatty-acid modification raises affinity for serum albumin and shields the chain from enzymes, as shown in the semaglutide discovery paper. Retatrutide is described as lipidated, which fits the same general design approach.
How much of a 6-day half-life is left after 12 days?
Under a first-order model with a 6-day half-life, 25% remains after 12 days (two half-lives). The table above gives the other whole half-lives.
Does a half-life measured in people apply to mice or mini-pigs?
Not automatically. Half-life depends on species, route and matrix. The semaglutide paper's 46.1 hour value, for example, comes from mini-pigs.
Does a certificate of analysis show half-life?
No. A report from an analytical lab lists identity, purity, measured quantity and, where included, endotoxin. Half-life comes from pharmacokinetic studies.
Does V8 Peptides publish a lab report for retatrutide?
Yes. Accumark Labs reports for the 10 mg and 20 mg sizes are on the COA page, showing HPLC purity and identity for the tested lots.
Is this page advice for use in people?
No. V8 sells retatrutide for laboratory research only. The page summarises published pharmacokinetic data and makes no claims about use in people or animals.
All V8 Peptides products are sold for laboratory research use only. They are not drugs, foods, or cosmetics and are not intended for human or animal consumption. This article describes published research and makes no claims about use in people or animals.
References
- Tetelbaun L, Mullally JA, Frishman WH. The First Triple Agonist for Antiobesity: Retatrutide. Cardiol Rev. 2026;34:575-579. PubMed 39724554 · doi:10.1097/CRD.0000000000000793
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34:1234-1247. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
- Mateescu DM, Capraru ID, Enache B, et al. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence. Pharmaceutics. 2026;18. PubMed 42942810 · doi:10.3390/pharmaceutics18101277
- Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58:7370-80. PubMed 26308095 · doi:10.1021/acs.jmedchem.5b00726
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PubMed 31031702 · doi:10.3389/fendo.2019.00155
